SPYRE THERAPEUTICS INC
SYRENASDAQ🏆 #814 by market capEarnings Nov 2US Equity
$102.74▼ $2.53 (−2.46%)
🌅 Pre-market$103.01▲ 0.26%Regular close · extended-hours price shown1h—
24h▼ 2.5%
7d▼ 1.6%
14d▲ 5.0%
30d▲ 9.7%
1y▲ 545.8%
🏦Market Cap
$8.92B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
7550.7x
Expensive
Otter Score
61
Fair
📊
Analyst Ratings
Price
$102.74
Total
13
Raised
0
Lowered
1
Avg PT
$105.36
H / L
$135 / $49
| Institution | Action | Rating | Date |
|---|---|---|---|
Wedbush | Reiterated | Outperform | 2026-08-05 |
Wells Fargo | Reiterated | Overweight | 2026-08-05 |
Guggenheim | Reiterated | Buy | 2026-08-05 |
Wolfe Research | Downgraded | Outperform → Peer Perform | 2026-07-28 |
Mizuho | Reiterated | Outperform | 2026-07-13 |
Deutsche Bank | Reiterated | Buy | 2026-06-23 |
BTIG | Reiterated | Buy | 2026-06-15 |
Citigroup | Reiterated | Buy | 2026-05-06 |
Stifel | Reiterated | Buy | 2026-05-06 |
Jones Trading | Reiterated | Buy | 2026-04-17 |
Baird | Reiterated | Outperform | 2026-04-14 |
Leerink Partners | Reiterated | Outperform | 2026-04-13 |
Jefferies | Reiterated | Buy | 2026-04-13 |
One row per institution, most recent rating